Autolus Therapeutics plc AUTL

AUTL Company Overview

Autolus Therapeutics plc is a clinical-stage biopharmaceutical company focused on developing programmed T cell therapies for the treatment of cancer. The company primarily operates within the immuno-oncology and cell therapy sectors, with a strategic emphasis on engineered chimeric antigen receptor T-cell (CAR-T) therapies designed to improve efficacy, safety, and persistence compared with earlier generations of CAR-T products. Autolus generates value through the research, development, and potential commercialization of proprietary T-cell programming technologies targeting hematologic malignancies and, to a lesser extent, solid tumors.

The company’s lead product candidate is obe-cel (obecabtagene autoleucel), an autologous CD19 CAR-T therapy developed for relapsed or refractory B-cell acute lymphoblastic leukemia (B-ALL). Autolus has also advanced additional pipeline programs targeting cancers through proprietary binder and cell-programming technologies. The company was founded in 2014 as a spin-out from University College London and built around research originating from leading academic institutions in cellular immunotherapy. Since its founding, Autolus has expanded from a UK-based research enterprise into a publicly traded biotechnology company listed on Nasdaq under the ticker AUTL.